Webinar: Maximising the impact of a COVID-19 vaccine in an ageing world
Date: Tuesday 15 December 2020
Time: 2.00pm – 3.30pm GMT
There is significant global interest in the development of a COVID-19 vaccine. We are bringing together senior representatives from the pharmaceutical industry and immunisation experts to discuss the impact a successful vaccine / vaccines would have in an ageing world.
We will be discussing:
- Progress towards a COVID-19 vaccine
- Who should be at the front of a queue for a COVID-19 vaccine?
- How can we ensure high uptake of a COVID-19 vaccine among adults in the UK and across the world?
Whilst childhood immunisations programmes are common and well delivered across the world, the situation for adult immunisation is very different.
The levels of uptake of existing adult vaccinations against Influenza, Pneumococcal disease and Herpes Zoster remain low across most of the world.
We’ve had an age-related flu vaccination programme in the UK for twenty years but we still fail to meet the WHO target of 75% uptake among older people. Clinical risk groups fare even worse with far too few people in these groups taking up their rights to vaccination. And only one in two pregnant women take up their entitlement to a free flu vaccination.
With an overwhelmed NHS, and many “at risk” groups and older people shielding or reluctant to get out of the home, it will be even harder to reach those most in need.
The UK remains a world leader in terms of its approach to the vaccination of older people. Government has started to build an infrastructure for delivery of a COVID-19 vaccine. And it has said it wants to ensure that the most vulnerable to the coronavirus get access to the vaccination first.
This webinar will explore how we head the lessons of what works, based on our experience of delivering other adult vaccinations.
- Dr. Dilruwan Herath, Executive Medical Director, MSD UK
- Gillian Ellsbury , Medical Director – Vaccines UK & Ireland , Pfizer
- Philip Cruz, MD, Vaccines Medical Director – UK & Ireland, GSK
Join us by registering below.